Getting In on M&A A...
Health Care: Drugs
Depomed Inc. (DEPO: NASDAQ)
$3.86 -0.06 | -1.53%
09/03/10 - 04:00 PM ET
248.31K / 311.60K
Vol / Avg. Vol:3.97 / 3.92
Open / Prev. Close:3.77 - 3.99
Today's Range:2.32 - 6.40
52 Wk Range:15.22%
Performance YTD:TheStreet Rating:
Portfolios with DEPO
- Portfolio NameUser Type
- ProThird Point
- ProDeltec Asset Management LLC
- ProPerceptive Advisors LLC
- Usergbwineman Portfolio 1
- UserLTR7181 Portfolio 1
- Userfrankie'spicks
- UserLou & Jeanette's Holdings
- Userport1p1
- Usertlbba06 Portfolio 1
- UserMbledug's First
Latest DEPO Headlines from TheStreet
- Depomed Reaches SPA Agreement With FDA For Phase 3 Hot Flash Trial 08.11.10 | 07:08 am
- Depomed Licenses GLUMETZA(R) Data And Acuform(R) Technology 08.05.10 | 04:08 pm
- Depomed Reports Second Quarter 2010 Financial Results 08.05.10 | 04:08 pm
- Depomed Receives Confirmation From Pfizer That No Infringement Suit To Be Filed On DM-1796 NDA 08.03.10 | 04:08 pm
- Depomed To Announce Second Quarter 2010 Financial Results On August 5, 2010 07.29.10 | 06:07 pm
- Depomed Announces Receipt Of A $10 Million Milestone Payment For DM-1796 06.28.10 | 05:06 pm
- Ambac Financial, DepoMed: Early Volume Plays 06.08.10 | 08:06 am
- Depomed Announces Acceptance Of New Drug Application For Investigational Postherpetic Neuralgia Treatment DM-1796 06.07.10 | 04:06 pm
- Zanett, Conexant: Early Volume Plays 03.05.10 | 08:03 am
- XenoPort, AMICAS: Early Volume Plays 02.22.10 | 09:02 am
Press Releases for DEPO
- New Clinical Study Shows Patients With Type 2 Diabetes May Be Able To Tolerate Higher Doses Of Metformin Using GLUMETZA - PR Newswire 06.28.10 | 08:06 am
- Depomed To Present At The 9th Annual JMP Securities Research Conference - Business Wire 05.04.10 | 08:05 am
- Depomed To Present At The Deutsche Bank 35th Annual Health Care Conference - Business Wire 04.29.10 | 04:04 pm
- Depomed Reports First Quarter 2010 Financial Results - Business Wire 04.29.10 | 04:04 pm
- Depomed To Announce First Quarter 2010 Financial Results On April 29, 2010 - Business Wire 04.22.10 | 08:04 am
- Depomed To Present At The BioCentury And Thomson Reuters Future Leaders In The Biotech Industry Conference - Business Wire 03.31.10 | 07:03 pm
- Depomed Announces Submission Of New Drug Application For Investigational Postherpetic Neuralgia Treatment DM-1796 - Business Wire 03.30.10 | 04:03 pm
- Depomed To Present At The ROTH 22nd Annual OC Growth Stock Conference - Business Wire 03.08.10 | 08:03 am
- Depomed To Present At The Cowen And Company 30th Annual Health Care Conference - Business Wire 03.02.10 | 08:03 am
- Depomed To Announce Fourth Quarter And Year-End 2009 Financial Results On March 4, 2010 - Business Wire 02.25.10 | 08:02 am
Partner Headlines for DEPO
- UPDATE 1-Depomed licenses drug technology rights to J&J unit - Reuters 08.05.10 | 05:08 pm
- UPDATE 1-Depomed says no lawsuit against pain drug; shares soar - Reuters 08.03.10 | 05:08 pm
- UPDATE 2-Depomed recalls 52 lots of diabetes drug - Reuters 06.17.10 | 10:06 am
- Depomed Announces Acceptance of New Drug Application for Investigational Postherpetic Neuralgia Treatment DM-1796 (DEPO) - Benzinga 06.07.10 | 04:06 pm
- Investment Opportunities in Women's Health - Seeking Alpha 06.04.10 | 04:06 pm
- Zacks Analyst Blog Highlights: Sony Corp., Kohl's Corp., Santarus, Inc., Merck and Depomed - Press Releases - Zacks 05.14.10 | 08:05 am
- Santarus Beats Expectations - Analyst Blog - Zacks 05.13.10 | 02:05 pm
- Zacks Bull and Bear of the Day Highlights: Depomed, King Pharmaceuticals, Pfizer Inc., MasterCard Inc. and Baker Hughes Inc. - Press Releases - Zacks 05.05.10 | 09:05 am
- Depomed, Inc. (DEPO) - Bull of the Day - Zacks 05.05.10 | 01:05 am
- Zacks Analyst Blog Highlights: General Electric Company, First Horizon National Corporation, Genuine Parts Company, Santarus and Depomed - Press Releases - Zacks 04.19.10 | 08:04 am
